Regulation of Pathogenic Plasma Cells in Human SLE
Regulation of Pathogenic Plasma Cells in Human SLE
批准号:
10187509
负责人:
Ignacio E. Sanz
金额:
$174.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-19 至 2022-05-31
关键词:
AcuteAddressAdultAirway DiseaseAntibodiesAntibody ResponseAntigensB-LymphocytesBiological AssayBloodBlood specimenBorrelia burgdorferiCOVID-19COVID-19 pandemicCellsClostridium difficileCollaborationsColorCoronavirusDataDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseExcisionFreezingGoalsGoldHealthHealth PersonnelHumanImmuneImmune responseImmunityImmunoassayImmunoglobulin-Secreting CellsImmunology procedureInfectionInfluenzaInvestigationLaboratoriesLeadLegal patentLicensingLower Respiratory Tract InfectionLyme DiseaseLyme InfectionNoseNucleocapsid ProteinsPathogenicityPatientsPeptidesPlasma CellsPneumoniaProteinsQuarantineRecording of previous eventsRegulationResolutionRespiratory FailureRespiratory syncytial virusRiskSamplingSerumSevere Acute Respiratory SyndromeStaphylococcus aureusStreptococcus pneumoniaeSwabSystemic Lupus ErythematosusTechnologyTestingTimeUniversitiesVaccinesValidationViralViral Load resultVirusVirus Diseasesacute infectionbasecommercializationfollow-upinfluenzavirusmicrobialneutralizing monoclonal antibodiesnovelnovel diagnosticsoutcome forecastpandemic diseaserespiratoryresponse
中文摘要
新冠肺炎新的免疫诊断方法对急性感染、重症预后和
感染的消退。
正在蔓延的新冠肺炎疫情再次突显了开发更好的诊断测试和
疫苗旨在通过以下途径增强有效的B细胞反应和被动治疗
注射中和单抗。我们的应用程序,将直接解决
新的免疫分析方法可以诊断急性新冠肺炎感染,为可能发生感染的患者提供预后
严重呼吸道并发症,并确定无症状成年人的免疫力和疾病解决
这场大流行的进程。
我们的实验室在B细胞和浆细胞对疫苗和流感病毒感染的反应方面拥有专业知识
为一种新的诊断平台提供基础,该平台在以下情况下询问循环抗体分泌细胞(ASC)
一位病人病了。这项技术可以诊断以下微生物感染:流感病毒,呼吸道
合胞病毒(RSV)1、2、肺炎链球菌、金黄色葡萄球菌
、艰难梭状芽胞杆菌(Clostridioidesfficile)
(Haddad等人,在回顾中)和伯氏疏螺旋体(莱姆病)。最初是用新鲜血液ASC在
繁琐的Elispot免疫分析,Microb-plex,Inc.的戴斯和李博士将这种分析简化为
一种专利技术,利用从分离的血液ASC中新分泌的抗体的培养上清液。
新的基质是Mensa,一种“富含新合成抗体的介质”,可以很容易地进行多路复用
含有超过10-12个抗原(如初步数据所示)。可以很容易地收集无细胞门萨基质并
冷冻,以评估患病时的同期ASC反应。此外,消极的门萨
确诊后可显示病毒的清除和主动免疫反应的消退。在这
作为补充,我们建议建立一种新的基于免疫的新冠肺炎门萨试验(1)来诊断急性白血病
感染和(2)以及预测有呼吸衰竭风险的患者。此外,通过决议
感染,新冠肺炎门萨阴性,血清试验阳性,表明对疾病有免疫力
决议。所有测试都将可用于商业化,而不需要为这种COVID19大流行专门发放许可证。
英文摘要
Novel Immune Diagnostics of COVID-19 for Acute Infection, Prognosis of Severe Disease, and
Resolution of Infection.
The spreading COVID-19 pandemic has once again highlighted the need to develop better diagnostic tests and
vaccines geared towards the enhancement of effective B cell responses and passive therapies through the
administration of neutralizing monoclonal antibodies. Our application, will directly address the development of
novel immune assays to diagnose acute COVID-19 infection, provide prognosis of patients who may develop
severe respiratory complications, and identify immunity and disease resolution in asymptomatic adults during
the course of this pandemic.
Our laboratories with expertise in B cells and plasma cell responses to vaccines and influenza virus infections
provide the basis for a novel diagnostic platform that interrogates circulating antibody secreting cells (ASC) when
a patient is ill. This technology can diagnose the following microbial infections: Influenza virus, Respiratory
syncytial virus (RSV) 1,2, Streptococcus pneumoniae, Staphylococcus aureus 3
, Clostridioides difficile (C. difficile)
(Haddad et al, in review), and Borrelia burgdorferi (Lyme disease). Originally performed with fresh blood ASC in
cumbersome Elispot immunoassays, Drs. Daiss and Lee at MicroB-plex, Inc. have streamlined the assay into a
patented technology that utilizes a cultured supernatant of newly secreted antibodies from isolated blood ASC.
The novel matrix is MENSA, a “media enriched with newly synthesized antibodies” and can be easily multiplexed
with over 10-12 antigens (as shown in preliminary data). The cell free-MENSA matrix can be easily collected and
frozen to evaluate the contemporaneous ASC responses at the time of illness. In addition, a negative MENSA
after diagnosis can demonstrate viral clearance and resolution of the active immune response. In this
supplement, we propose to develop a novel immune-based COVID-19 MENSA assay (1) to diagnose acute
infection and (2) and to prognosticate patients at risk of respiratory failure. In addition, with resolution of
infection, a negative COVID-19 MENSA and positive serum test will show immunity with disease
resolution. All tests will be available for commercialization without a need for licensing specific for this COVID19 pandemic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Regulation of B cells and T cells in Human SLE
-
批准号:10493525
-
项目类别:
-
资助金额:$8.88万
-
财政年份:2021
-
负责人:Ignacio E. Sanz
-
依托单位:
ACE Funds Management Core
-
批准号:10439991
-
项目类别:
-
资助金额:$17.17万
-
财政年份:2021
-
负责人:Ignacio E. Sanz
-
依托单位:
Molecular Regulation of B cells and T cells in Human SLE
-
批准号:10439989
-
项目类别:
-
资助金额:$17.17万
-
财政年份:2021
-
负责人:Ignacio E. Sanz
-
依托单位:
ACE Covid 19 Admin Supplement: Molecular Regulation of B cells and T cells in Human SLE
-
批准号:10456447
-
项目类别:
-
资助金额:$2679.42万
-
财政年份:2021
-
负责人:Ignacio E. Sanz
-
依托单位:
Administrative Supplement Covid19: Molecular Regulation of B cells and T cells in Human SLE
-
批准号:10164943
-
项目类别:
-
资助金额:$52.56万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Molecular Regulation of B cells and T cells in Human SLE
-
批准号:10265747
-
项目类别:
-
资助金额:$37.47万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
-
批准号:10680628
-
项目类别:
-
资助金额:$15.96万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
-
批准号:10680631
-
项目类别:
-
资助金额:$35.92万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
-
批准号:10222317
-
项目类别:
-
资助金额:$31.82万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Principal Project
-
批准号:10198495
-
项目类别:
-
资助金额:$52.56万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
-
批准号:10222320
-
项目类别:
-
资助金额:$79.55万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Project-002
-
批准号:10441807
-
项目类别:
-
资助金额:$56.09万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Molecular Regulation of B cells and T cells in Human SLE
-
批准号:10265746
-
项目类别:
-
资助金额:$56.09万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
-
批准号:10710093
-
项目类别:
-
资助金额:$54.51万
-
财政年份:2020
-
负责人:Ignacio E. Sanz
-
依托单位:
Plasma Cells in Health and Disease
-
批准号:10428164
-
项目类别:
-
资助金额:$269.59万
-
财政年份:2016
-
负责人:Ignacio E. Sanz
-
依托单位:
Plasma Cells in Health and Disease
-
批准号:10621320
-
项目类别:
-
资助金额:$269.13万
-
财政年份:2016
-
负责人:Ignacio E. Sanz
-
依托单位:
Project 1
-
批准号:10428167
-
项目类别:
-
资助金额:$55.02万
-
财政年份:2016
-
负责人:Ignacio E. Sanz
-
依托单位:
Project 4
-
批准号:10428170
-
项目类别:
-
资助金额:$54.2万
-
财政年份:2016
-
负责人:Ignacio E. Sanz
-
依托单位:
Administrative Core
-
批准号:10428165
-
项目类别:
-
资助金额:$10.18万
-
财政年份:2016
-
负责人:Ignacio E. Sanz
-
依托单位:
Administrative Core
-
批准号:10621322
-
项目类别:
-
资助金额:$10.18万
-
财政年份:2016
-
负责人:Ignacio E. Sanz
-
依托单位:
海外基金